Loading...
For patients with metastatic pancreatic cancer with a germline BRCA mutation who are responding to or stable on platinum-based chemotherapy, the PARP inhibitor olaparib was approved as maintenance therapy based on improved progression-free survival (PFS) reported in the POLO trial (NEJM JW Oncol Hematol Jun 26 2019; [e-pub] and N Engl J Med 2019; 381:317). Investigators now report an update of this industry-sponsored phase 3 trial in which 92 patients were randomized to olaparib and 62 to placebo.
At a median follow-up of 31.3 months for the olaparib group and 23.9 months for the placebo group, the hazard ratio (HR) for overall survival (OS) trended numerically but not statistically superior for olaparib versus placebo (HR, 0.83; P=0.3487), …